Company Overview
American Healthcare Capital is pleased to exclusively introduce an innovative MedTech developer that has created a technology breakthrough, patent-protected non-invasive, long-term pain management medical device to reduce pain caused by joint inflammation while promoting the process of tissue regeneration through a dedicated tissue regeneration device. The device improves daily function and performance, creating pain-free living. For the first time, both inflammation reduction and tissue restoration are addressed using a combination of electrical and thermal stimulation. This is a true breakthrough in pain management.
The device is FDA-approved as a Class I device for pain management. It is a Transcutaneous Electrical Joint Stimulation Device that delivers a deep three-dimensional electric field directly into the spinal or articular joints, promoting rapid & sustained joint pain relief, reduction in joint inflammation, and cartilage rejuvenation with smart cloud-supported technology. This combination of delivering DEEP Electric Field and Thermal Stimulation provides non-opioid, long-term pain relief for Acute and Chronic Spine and Joint Pain, enhancing functional mobility and positive cartilage rejuvenation.
The multi-platform device is intended for the treatment of chronic joint pain, the number one cause of disability in the world. It is a novel non-opioid, non-pharmacological product for chronic pain management and the treatment of osteoarthritis (OA). Chronic pain causes the incapability to carry out everyday chores. According to the Centers for Disease Prevalence and Control (CDC), over 58.5 million adults in the U.S. have arthritis. The CDC expected around 35 million individuals to be limited in their usual activities because of arthritis by 2040. This has propelled the market for pain management stimulators to control chronic pain.
The device supplies and supports remote therapeutic monitoring through the advanced communication system embedded in the device. The on-board microprocessor controls and monitors the therapy delivery, operational status, and tracks usage of the device. The intelligent controller permits uploading of patient usage data that is monitored and evaluated for patient adherence and device performance.
Financial Overview
The pain management with remote therapeutic monitoring company has ended its pre-revenue stage and has begun selling its first in a line of joint-specific products for treatment of pain and OA. The sales of its current device are “proof of concept” for the development and launch of the Next Generation of products in 2025 and 2026. The new devices under development have widespread use with advanced technology and maintain high gross profit margins. The channels of distribution for these pain management devices are huge with expected coverage in Integrated Group Clinical Practices, Chiropractic and Physical Therapy Practices and all areas of wellness settings. The Company is forecasting $16.6 million in revenues in 2027 with an Adjusted EBITDA of $4.9 million (29%).
Asking Price
The Company is looking for a strategic or financial partner to add value through its connections, financial strength, and resources to grow the Company to the next level. Therefore, the founders will consider a buyout in support of the future growth potential for this innovative technology platform.
The Price is to Be Determined with or without an Earnout Going Forward.
